Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBA OTCMKTS:CSLLY NYSE:GSK NYSE:GSK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$1.40+1.4%$1.10$0.82▼$4.04$370.20M0.235.65 million shs2.87 million shsCSLLYCSL$21.58+2.3%$19.03$16.01▼$44.86$40.42B0.58446,172 shs428,819 shsGSKGSK$51.27-1.9%$51.46$35.45▼$61.69$105.77B0.353.16 million shs3.32 million shsGSKGSK$51.27-1.9%$51.46$35.45▼$61.69$105.77B0.353.16 million shs3.32 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+1.45%+3.70%+51.43%-9.68%-64.74%CSLLYCSL+2.27%-0.46%+13.22%-15.04%-72.99%GSKGSK-1.96%-3.68%-3.34%-11.38%+33.75%GSKGSK-1.96%-3.68%-3.34%-11.38%+33.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$1.40+1.4%$1.10$0.82▼$4.04$370.20M0.235.65 million shs2.87 million shsCSLLYCSL$21.58+2.3%$19.03$16.01▼$44.86$40.42B0.58446,172 shs428,819 shsGSKGSK$51.27-1.9%$51.46$35.45▼$61.69$105.77B0.353.16 million shs3.32 million shsGSKGSK$51.27-1.9%$51.46$35.45▼$61.69$105.77B0.353.16 million shs3.32 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+1.45%+3.70%+51.43%-9.68%-64.74%CSLLYCSL+2.27%-0.46%+13.22%-15.04%-72.99%GSKGSK-1.96%-3.68%-3.34%-11.38%+33.75%GSKGSK-1.96%-3.68%-3.34%-11.38%+33.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 2.40Hold$4.67233.33% UpsideCSLLYCSL 1.80ReduceN/AN/AGSKGSK 2.10Hold$53.003.37% UpsideGSKGSK 2.10Hold$53.003.37% UpsideCurrent Analyst Ratings BreakdownLatest AKBA, CSLLY, GSK, and GSK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2026GSKGSK Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold7/9/2026GSKGSK Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold7/7/2026AKBAAkebia Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold7/6/2026GSKGSK HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeReduce ➝ Hold7/6/2026GSKGSK HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeReduce ➝ Hold7/1/2026AKBAAkebia Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.006/11/2026GSKGSK Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)6/11/2026GSKGSK Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)6/9/2026GSKGSK Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/9/2026GSKGSK Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/29/2026CSLLYCSL Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$236.20M1.59N/AN/A$0.12 per share11.67CSLLYCSL$15.56B2.66$2.24 per share9.65$11.05 per share1.95GSKGSK$43.07B2.41$5.89 per share8.71$10.32 per share4.97GSKGSK$43.07B2.41$5.89 per share8.71$10.32 per share4.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$5.34M-$0.08N/AN/AN/A-8.83%-62.72%-5.66%8/6/2026 (Estimated)CSLLYCSL$3.00BN/AN/A13.75N/AN/AN/AN/AN/AGSKGSK$7.54B$3.8513.3210.193.3617.82%44.28%11.49%7/28/2026 (Estimated)GSKGSK$7.54B$3.8513.3210.193.3617.82%44.28%11.49%7/28/2026 (Estimated)Latest AKBA, CSLLY, GSK, and GSK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026AKBAAkebia Therapeutics-$0.03N/AN/AN/A$48.85 millionN/A7/28/2026Q2 2026GSKGSK$1.27N/AN/AN/A$11.02 billionN/A7/28/2026Q2 2026GSKGSK$1.27N/AN/AN/A$11.02 billionN/A5/7/2026Q1 2026AKBAAkebia Therapeutics-$0.01-$0.03-$0.02-$0.03$51.67 million$53.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/ACSLLYCSL$0.592.73%N/AN/AN/AGSKGSK$1.793.49%-7.86%46.49%N/AGSKGSK$1.793.49%-7.86%46.49%N/ALatest AKBA, CSLLY, GSK, and GSK DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2026GSKGSKquarterly$0.443.71%5/15/20265/15/20267/9/20264/29/2026GSKGSKquarterly$0.443.71%5/15/20265/15/20267/9/20261/1/2100GSKGSKquarterly$0.42064.3%8/15/20258/15/202510/9/20251/1/2100GSKGSKquarterly$0.42064.3%8/15/20258/15/202510/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia Therapeutics1.331.401.33CSLLYCSL0.512.571.15GSKGSK0.800.790.52GSKGSK0.800.790.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%CSLLYCSL0.03%GSKGSK15.74%GSKGSK15.74%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics4.30%CSLLYCSLN/AGSKGSK10.00%GSKGSK10.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430268.26 million256.72 millionOptionableCSLLYCSL29,9041.92 billionN/ANot OptionableGSKGSK66,8412.02 billion1.82 billionOptionableGSKGSK66,8412.02 billion1.82 billionOptionableAKBA, CSLLY, GSK, and GSK HeadlinesRecent News About These CompaniesGSK slides Tuesday, underperforms marketJuly 14 at 10:37 PM | marketwatch.comGSK's Jemperli Delivers Promising Interim Data in Rectal CancerJuly 14 at 12:28 PM | finance.yahoo.comGSK's Jemperli Delivers Promising Interim Data in Rectal CancerJuly 14 at 9:31 AM | zacks.comUnilever to acquire GSK health food portfolio for 3.1 bn poundJuly 14 at 1:47 AM | zeenews.india.comZUBS keeps GSK at 'neutral' with focus on chief executive's strategy updateJuly 13 at 3:39 PM | proactiveinvestors.comUBS keeps GSK at 'neutral' with focus on chief executive's strategy updateJuly 13 at 9:30 AM | proactiveinvestors.co.ukGSK rectal cancer drug shows positive result in key trialJuly 13 at 9:00 AM | sharecast.comSGSK Reports Encouraging Phase II Results for Jemperli in Rectal Cancer Study (GSK)July 13 at 9:00 AM | uk.finance.yahoo.comGSK's Jemperli yields yearlong disease-free responses in dMMR/MSI-H rectal cancerJuly 13 at 9:00 AM | newsbytesapp.comNGSK’s partner Hansoh Pharma succeeds in Chinese Phase III SCLC ADC trialJuly 13 at 9:00 AM | yahoo.comGSK's Jemperli meets main goal in mid-stage rectal cancer trialJuly 13 at 3:15 AM | reuters.comGSK PLC Sponsored ADR (NYSE:GSK) Given Consensus Recommendation of "Hold" by AnalystsJuly 12 at 12:28 PM | marketbeat.comGSK's targeted cancer therapy shows positive results in late-stage studyJuly 10, 2026 | reuters.comGSK ends Alector alliance as both lead assets failJuly 9, 2026 | emjreviews.comEAstraZeneca, GSK intensify China ties with Sino Biopharm dealsJuly 8, 2026 | finance.yahoo.comSino Biopharma receives Chinese rights to two GSK respiratory drugsJuly 8, 2026 | seekingalpha.comSino Biopharm Strikes Drug Licensing Deal With AstraZeneca, Deepens Partnership With GSK -- UpdateJuly 8, 2026 | marketwatch.comSino Biopharm strikes drug licensing deal with AstraZeneca, deepens GSK partnershipJuly 8, 2026 | msn.comSino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugsJuly 7, 2026 | reuters.comGSK advances Thursday, outperforms marketJuly 2, 2026 | marketwatch.comGSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per ShareJune 30, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKBA, CSLLY, GSK, and GSK Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$1.40 +0.02 (+1.45%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$1.39 -0.01 (-0.71%) As of 06:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.CSL OTCMKTS:CSLLY$21.58 +0.48 (+2.27%) As of 07/14/2026 03:59 PM EasternCSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.GSK NYSE:GSK$51.27 -1.02 (-1.94%) Closing price 07/14/2026 03:59 PM EasternExtended Trading$51.13 -0.15 (-0.29%) As of 08:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.GSK NYSE:GSK$51.27 -1.02 (-1.94%) Closing price 07/14/2026 03:59 PM EasternExtended Trading$51.13 -0.15 (-0.29%) As of 08:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet 3 Overlooked Energy ETFs Delivering Strong Returns and Income 3 Space Stocks That Could Outshine SpaceX After Its IPO 3 Energy Stocks Racing to Fix AI's Power Problem JPMorgan’s Q2 Strength Gives the Stock Rally New Support No Space For Panic: T-Mobile Shrugs Off The Starlink Threat Prepare for the Next Wave of Factory Automation With These 3 Standout Names Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
